Drugs / Intravenous Immunoglobulin Therapy
Intravenous Immunoglobulin Therapy
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT04438382 | Jan 2021 → Dec 2023 | cancer, hematopoietic and lymphoid cell neoplasm | ECOG-ACRIN Cancer Research Group | Terminated | No outcome recorded Stop: Enrollment |
| Phase 31 trial | ||||||
| Phase 3 | NCT04548557 | Sep → Oct 2020 | COVID-19 | University of Health Sciences Lahore | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | intravenous immunoglobulin therapy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04548557 ↗ |
| Modality | Protein / enzyme biologic | “small scale concentrates of immunoglobulins prepared from convalescent plasma collections provide higher potency and greater consistency than individual units” NCT04548557 ↗ |
| Route | Intravenous | “Given IV” NCT04438382 ↗ |